A widely used blood pressure medication, telmisartan, could significantly boost the effectiveness of the cancer drug olaparib, according to new research. Scientists found that combining the two treatments enhanced the body’s immune response against tumors and improved anticancer activity in preclinical studies. The findings suggest that olaparib’s benefits may extend beyond patients with BRCA-related cancers, potentially helping a much broader group of cancer patients. Encouragingly, this promising drug combination has already advanced to human clinical trials, where researchers are evaluating its safety and effectiveness. If successful, this approach could offer a more powerful and accessible strategy for cancer treatment in the future.
Read more at ScienceDaily